News & Trends - Pharmaceuticals

Lilly’s psoriasis drug superior to Novartis’ Cosentyx in head-to-head trial

Health Industry Hub | July 24, 2020 |
[Total: 1    Average: 5/5]

Pharma News: Eli Lilly announces its win in a head-to-head trial against Novartis’ big-selling Cosentyx (secukinumab) in moderate to severe plaque psoriasis.

Mirikizumab, a monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at week 16 (superiority) and all key secondary endpoints versus Novartis’ Cosentyx (secukinumab) at week 16 (non-inferiority) and week 52 (superiority) in the OASIS-2 study.

Novartis’ Cosentyx brought in US$3.6 billion in sales last year in psoriasis and other indications like psoriatic arthritis and ankylosing spondylitis.

Lilly is investing heavily to catch up with Cosentyx and other new psoriasis antibodies, including AbbVie’s Skyrizi (risankizumab), Janssen’s Tremfya (guselkumab) and Sun Pharma’s Ilumya (tildrakizumab) which are PBS listed.

“We are pleased with the positive results observed in the mirikizumab psoriasis development program (OASIS). Mirikizumab has the potential to be a meaningful treatment option for people living with psoriasis,” said Andrew Blauvelt, M.D., M.B.A., president of Oregon Medical Research Centre and a lead investigator in the OASIS program. “The data builds on our understanding of IL-23 inhibition in psoriasis and possible future applications.” 

Lilly is also running large-scale phase III trials of mirikizumab in ulcerative colitis (UC) and Crohn’s disease to expand the potential uses of the monoclonal antibody.

Lilly expects topline results for the Phase III induction data in UC in 2021 and for the Phase III Crohn’s data in 2022.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - State first heart procedure with non-invasive technology most commonly used to combat cancer

State first heart procedure with non-invasive technology most commonly used to combat cancer

Health Industry Hub | August 4, 2020 |

MedTech News: A team of cardiologists and radiation oncologists from Fiona Stanley Hospital (FSH) and GenesisCare, have become the first […]

More


News & Trends - Pharmaceuticals

Pharma News - Medicines Australia calls for a focus in planning Australia's future in health

Medicines Australia calls for a focus in planning Australia’s future in health

Health Industry Hub | August 4, 2020 |

Pharma News: Medicines Australia Chief Executive Officer, Elizabeth de Somer has urged a focus on planning for the future – […]

More


News & Trends - Medical Technology

MedTech News - Australian-first procedure for chronic pain sufferers

Australian-first procedure for chronic pain sufferers

Health Industry Hub | August 3, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trendsmenu →Medical Technology’ sub-menu.

More


News & Trends - Pharmaceuticals

Pharma News - New PBS listings in lung cancer, epilepsy and ovarian cancer – AstraZeneca, Roche, Pfizer and Emerge Health

New PBS listings in lung cancer, epilepsy and ovarian cancer – AstraZeneca, Roche, Pfizer and Emerge Health

Health Industry Hub | August 3, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trendsmenu →Pharmaceuticals’ sub-menu.

More